AIDS 2024, the 25th International AIDS Conference, is just two weeks away! Take a look at some of the cutting-edge late-breaker research highlights you can expect at the world’s largest conference on HIV and AIDS in Munich, Germany, and virtually.

Register today for AIDS 2024 from 22 to 26 July.

Some research highlights to expect at AIDS 2024

  • The “next Berlin Patient”, a person experiencing sustained HIV remission without antiretroviral therapy after heterozygous CCR5 WT/delta32 allogeneic hematopoietic stem cell transplantation 

  • Important new data from the PURPOSE 1 trial, which found that twice-yearly injectable lenacapavir demonstrated 100% efficacy for HIV prevention in cisgender women 

  • Data from the PASO-DOBLE trial showing non-inferior efficacy and less weight gain when switching to DTG/3TC vs. BIC/FTC/TAF in virologically suppressed people living with HIV 

  • Results of a pilot randomized controlled trial of doxycycline pre-exposure prophylaxis (DoxyPrEP) for prevention of bacterial STIs in gay men and other men who have sex with men who are living with HIV 

  • New findings from DTG Resist, a large multi-country study on dolutegravir resistance patterns in central, eastern, southern and western Africa 

  • Insights from a first-of-its-kind survey showing significant HIV stigma and discrimination among European healthcare workers 

All AIDS 2024 abstracts are now available in the programme.